Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for rare disease: drug targets stubborn Behcet's symptoms

NCT ID NCT01532570

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jan 07, 2026 · Last updated Apr 28, 2026 · Updated 23 times

Summary

This study tested a drug called TA-650 (also known as infliximab) in 18 people with Behcet's disease who had serious symptoms like ulcers or brain inflammation that didn't get better with standard treatments. The drug was given as an infusion at weeks 0, 2, and 6, then every 8 weeks up to week 46. The goal was to see if symptoms completely disappeared and if tests like scans or blood markers improved. This is a disease-control approach, not a cure, as ongoing treatment is needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BEHCET'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Investigational site

    Chūbu, Japan

  • Investigational site

    Hokkaido, Japan

  • Investigational site

    Kanto, Japan

  • Investigational site

    Kinki, Japan

  • Investigational site

    Kyusyu, Japan

  • Investigational site

    Tōhoku, Japan

Conditions

Explore the condition pages connected to this study.

BEHCET SYNDROME BEHCET'S DISEASE NEURO-BEHCET'S DISEASE